The Korean Ministry of Food and Drug Safety (MFDS) approved a total of 36 patents in February.
According to the MFDS’ information platform (https://nedrug.mfds.go.kr/), Tabrecta-related (Novartis) patents accounted for the most with six, followed by Invega Sustenna Inj. (Janssen Korea) with five among the 36 patents.
A total of four cases were registered for Ajovy (Teva-Handok), two each for Auto Injector Inj. and Prefilled Syringe Inj., while three cases were listed for Byfavo Inj. (Hana Pharm), Velexbru Tab. (Ono Pharmaceutical Korea), and Cibinqo Tab. (Pfizer Pharmaceutical Korea).
Moreover, AKLIEF Cream (Galderma Korea), Tepmeko Tab. (Merck), Skilarence Enteric Coated Tab. (Kolon Pharmaceutical), Tagrisso Tab. (AstraZeneca Korea), and Abilify Tab. (Korea Otsuka Pharmaceuticals) secured two cases each, and Covid-19 Vaccine Janssen Inj. (Janssen Korea) and Tecentriq Inj. (Roche Korea) one case.
By company, Novartis and Janssen were approved the most by six cases. Teva-Handok had four cases, and Hana Pharm, Ono Pharmaceutical Korea, and Pfizer Pharmaceutical Korea three cases.
Galderma Korea, Merck, Kolon Pharmaceutical, AstraZeneca Korea, and Korea Otsuka Pharmaceuticals followed with two cases, while Roche listed one.
